To battle against COVID-19, scientists around the world are racing against time to accelerate the development of new treatments and vaccines. China has pledged that its COVID-19 vaccine will be made a global public good when it's available.

Meanwhile, Britain is also seeing progress in the development of another vaccine candidate. A separate study published Monday in The Lancet reveals the results of the phase 1/2 trial of the Oxford coronavirus vaccine ChAdOx1 nCoV-19. It indicates no early safety concerns and produces strong immune response.

According to the Oxford University, the trial involves more than 1000 healthy adult volunteers. The vaccine provoked a T cell response (white blood cells that can attack cells infected with the SARS-CoV-2 virus) within 14 days of vaccination, and an antibody response within 28 days.

Despite the promising findings, it is still too soon to know if this is enough to offer protection and larger trials are under way, scientists involved in this study said.

【国际英语资讯:Chinas phase 2 trial finds COVID-19 vaccine safe, inducing immune response -- The Lancet】相关文章：

★ 亚洲为何需要“亚盟”？

★ 奥巴马为缅甸之行辩护

★ 双语美文：人生中的“蝴蝶效应”

★ 六大妙招教您如何提升幸福感（图组）

★ 高价蓝光影碟超清晰画质纯属骗人？

★ 日本新财相：将发债刺激经济

★ 在YouTube上淘金

★ 不能轻视创造财富

★ 情人节在即 马尼拉上演浪漫集体拥吻

★ 美国需要一个整合的商务部